



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 04/21/2022 17:43
Last Report Issued 01/19/2015 12:14

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 2527B
Patient ID 2527B
Chain 15000133
DOB Not Given
Sex Not Given
Workorder 15000133
Received 01/19/2015

Lab ID 15000133-001
Matrix Blood
Patient Name 2527B
Patient ID 2527B
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

2527B Lacosamide, Blood

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Lacosamide	None Detected	mcg/mL	0.50	
------------	---------------	--------	------	--

Synonym(s): Vimpat®

Peak plasma concentrations are reached 1 to 2 hours after a single oral or intravenous dose with a half-life of 13 hours.

Following a single 200 mg dose administered as a 30-minute infusion, a 60-minute infusion, or orally as a tablet to 24 male subjects, mean maximum plasma lacosamide concentrations were 5.95 +/- 1.49, 5.38 +/- 1.10 and 5.15 +/- 1.4 mcg/mL, respectively.

Mean plasma concentrations following maintenance doses:

200 mg/day: 4.99 +/- 2.51 mcg/mL;
400 mg/day: 9.35 +/- 4.22 mcg/mL;
600 mg/day: 12.46 +/- 5.60 mcg/mL.

The ratio of whole blood concentration to plasma concentration is 1.1.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.